C-Bridge Capital has announced a licensing agreement with Samsung Bioepis that is intended to help the Korean biopharmaceutical specialist expand into the China market.
The private equity firm will establish a new entity, AffaMed Therapeutics, which will collaborate with Samsung Bioepis in areas such as clinical development, regulatory registration and commercialization...
Rhetoric shaping the debate over China's ambitions to become the prime mover in global technology - and what the US could do in response - reflects the geopolitical significance of the issue. Private equity investors are not immune to its impact
Novo Tellus Capital Partners has invested S$12 million ($8.8 million) in Procurri, a Singapore-listed provider of IT services and data center equipment.
Australia’s Anacacia Capital has realized the final exit from its debut fund with the sale of its majority stake in workplace equipment provider RIS Safety to domestic investor Bricktop Group.
Bain Capital has acquired a majority interest in the data center construction and maintenance division of Shenzhen-listed NetScience Technology for RMB990 million ($147 million).